Yes, but the value of an ODD is recognised only once a drug is approved in that indication - the value being market exclusivity for a time and a priority review voucher to be used or sold (FDA, not sure about UK).
So if we get approval for IIH, we lock in the benefits of the ODD that was assigned to that indication. But the new ODD then becomes worthless.
So this new ODD, while still awesome news and recognition, is really only of value if we are unsuccessful in IIH but eventually successful in TBI.
Ann: Invex Granted European Orphan Drug Designation for TBI, page-46
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.960M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable